Korro Bio updates investor presentation slides

Korro Bio, Inc. filed a current report to note that it has updated its corporate presentation.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Korro Bio, Inc. filed a current report to note that it has updated its corporate presentation. On January 15, 2026, the company prepared new materials for use in meetings with investors, analysts, and other audiences, and filed selected updated slides as an exhibit. These slides, dated January 15, 2026, are incorporated by reference as part of the report, giving stakeholders an officially filed version of the latest overview of the company and its business.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Korro Bio (KRRO) report in this 8-K filing?

Korro Bio, Inc. reported that it updated its corporate presentation for use in meetings with investors, analysts, and others, and filed selected updated slides as an exhibit.

When did Korro Bio (KRRO) update its corporate presentation?

Korro Bio updated its corporate presentation on January 15, 2026, and used that date on the slides filed with the report.

Which exhibit contains the updated Korro Bio (KRRO) investor slides?

The updated investor slides are included as Exhibit 99.1, titled "Selected Slides from Corporate Presentation of Korro Bio, Inc., dated January 15, 2026."

Does this Korro Bio (KRRO) filing include financial statements?

The filing lists Exhibit 99.1 with selected corporate presentation slides and an Exhibit 104 cover page interactive data file; it does not add separate financial statements.

Who signed this Korro Bio (KRRO) 8-K report?

The report was signed on behalf of Korro Bio, Inc. by Ram Aiyar, President and Chief Executive Officer and Interim Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/15/2026 - 04:05 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2026

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-39062	47-2324450
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
60 First Street, 2nd floor, Suite 250 Cambridge, MA		02141
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 468-1999

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	KRRO	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 15, 2026, Korro Bio, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

99.1		Selected Slides from Corporate Presentation of Korro Bio, Inc., dated January 15, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	KORRO BIO, INC.

Date: January 15, 2026	By:	/s/ Ram Aiyar

		Name: Ram Aiyar
		Title: President and Chief Executive Officer and Interim Chief Financial Officer

Source: View Original Filing on SEC EDGAR